Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2020 Dec 02

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Medica 2020 Dec 02

DOI: 10.23736/S0026-4806.20.07158-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Rheumatologic manifestations of Hepatitis C Virus

Elena TREPPO 1, Luca QUARTUCCIO 1 , Gaafar RAGAB 2, Salvatore DE VITA 1

1 Rheumatology Clinic, Department of Medicine, University of Udine, ASUFC, Udine, Italy; 2 Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt


PDF


INTRODUCTION: Hepatitis C Virus (HCV) is a well-known worldwide infection, responsible for hepatic and extrahepatic complications. Among extrahepatic manifestation, the rheumatologic are the most common ones. With the arrival of Direct Antiviral Agents (DAA), the treatment and the clinical perspective have rapidly changed, permitting to achieve a sustained virological response (SVR) and preventing complications of chronic infection.
EVIDENCE ACQUISITION: We performed on PubMed a literature search for the articles published by using the search terms “HCV infection”, “HCV syndrome”, “HCV-related rheumatologic disorders”, “cryoglobulinaemia”, “cryoglobulinaemic vasculitis”, “mixed cryoglobulinaemia”.
EVIDENCE SYNTHESIS: Mixed cryoglobulinaemia (MC) is the prototype of HCVassociated rheumatologic disorder. HCV-related MC is typically considered by physicians as a human model disease to linking infection with autoimmune diseases. Chronic HCV infection can lead to a multistep process from a simple serological alteration (presence of circulating serum cryoglobulins) to frank systemic vasculitis (cryoglobulinaemic vasculitis (CV)) and ultimately to overt malignant B lymphoproliferation (such as non-Hodgkin lymphoma (NHL)). Antiviral therapy is indicated to eradicate the HCV infection and to prevent the complications of chronic infection. Immunosuppressive therapy is reserved in case of organ threatening manifestations of CV. In this review, we discuss the main clinical presentation, diagnostic approach and treatment of rheumatologic manifestations of HCV infection.
CONCLUSIONS: Chronic HCV infection is responsible for complex clinical condition, ranging from hepatic to extra-hepatic disorders. Cryoglobulins are the result of this prolonged immune system stimulation, caused by tropism of HCV for B-lymphocyte.


KEY WORDS: HCV infection; Cryoglobulinaemia; Cryoglobulinaemic vasculitis; Sjögren Syndrome; Direct Antiviral Agents

top of page